# PH 2 ADI-PEG 20 Acute Myeloid Leukemia

> **NCT01910012** · PHASE2 · COMPLETED · sponsor: **Polaris Group** · enrollment: 43 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** ADI-PEG 20

## Key facts

- **NCT ID:** NCT01910012
- **Lead sponsor:** Polaris Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-06
- **Primary completion:** 2016-09-12
- **Final completion:** 2017-05-05
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2020-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01910012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01910012, "PH 2 ADI-PEG 20 Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01910012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*